Wegovy and MACE reduction: separating the evidence from the hype

The misconception worth clearing up first: Wegovy is not just a weight drug that happens to help the heart

A lot of the coverage around semaglutide frames the cardiovascular finding as a bonus, a pleasant side effect of losing weight. The SELECT trial was designed specifically to test whether semaglutide reduces heart events, and it did, with a 20% relative risk reduction in MACE compared to placebo. More striking still: participants in SELECT had not lost significant weight before the cardiovascular benefit emerged, which suggests the mechanism is not purely about kilograms shed.

That matters because it shifts the question. For people with existing cardiovascular disease, the conversation with a prescriber is no longer limited to "will I lose enough weight?", it now includes whether the cardiovascular protection itself is relevant to them. Weight loss and heart protection appear to work through overlapping but distinct pathways: appetite regulation, inflammation, blood pressure, lipids and direct cardiac effects are all under active investigation.

Wegovy's cardiovascular indication covers adults with established heart disease and a BMI of 28 or above. That lower BMI threshold (28 rather than the usual 30) reflects the trial population. If cardiovascular risk reduction is your primary reason for interest in semaglutide, it is worth reading the SELECT trial findings in detail and discussing them with a clinician who can map the evidence to your own history.

Who the cardiovascular evidence applies to, and what SELECT did not cover

SELECT recruited adults aged 45 or over with a body mass index of 28 or above and established cardiovascular disease, meaning a prior heart attack, stroke or peripheral artery disease. Crucially, none of them had type 2 diabetes at enrolment; this was a deliberate design choice to separate the cardiovascular effect from glycaemic improvement. The trial ran across 41 countries and followed participants for up to five years.

The 20% relative reduction translated to around 1.5 fewer MACE events per 100 participants over the trial period, what researchers call a number needed to treat of roughly 67 for around three years of treatment. Whether that matters to an individual depends heavily on their baseline cardiovascular risk, which a prescriber calculates from their personal history, not population averages.

What SELECT did not establish: whether the same cardiovascular benefit applies to people without existing heart disease, to those with type 2 diabetes (different trials cover that), or to those using Wegovy purely for weight management who happen to have a healthy heart. The full overview of Wegovy's licensed indications explains how the weight-management and cardiovascular licences sit alongside each other in the UK.

The MHRA approves medicines for specific populations in specific contexts, and the cardiovascular approval is no exception. Semaglutide remains a prescription-only medicine regardless of which indication applies.

Side effects, long-term use and practical points for people with cardiovascular conditions

The side-effect profile in SELECT was broadly consistent with what weight-management trials found: gastrointestinal symptoms (nausea, loose stools, reduced appetite, occasional vomiting) were the most commonly reported, concentrated in the early weeks of treatment as the body adjusts. Most participants managed these without stopping. Serious adverse events were lower in the semaglutide group than in the placebo group overall, which is an encouraging signal though not a guarantee for any individual.

People with cardiovascular disease often take multiple medicines: antiplatelets, statins, antihypertensives, sometimes anticoagulants. Semaglutide does not have major pharmacokinetic interactions with most of these, but slowed gastric emptying can affect the absorption timing of oral medicines taken alongside it. Reviewing your whole medicine list with a prescriber before starting is straightforward and sensible.

A practical note for anyone already on treatment: semaglutide injections need refrigeration. Many people keep the current pen in the fridge door alongside everyday items, which is fine as long as it stays between 2°C and 8°C. Once started, the pen can be kept at room temperature for a limited period, check the Patient Information Leaflet for the exact window, because it does matter. The semaglutide medicines page has further practical detail on storage and routine.

If you experience severe, persistent stomach pain (especially if it radiates towards your back) seek medical help promptly. Some people also notice changes to their appearance during treatment, including what is sometimes called Wegovy face, a shift in facial volume that can accompany significant weight loss, and it is worth being aware of before you start. The MHRA's Yellow Card scheme allows patients and carers to report suspected side effects directly to the regulator, which is always worth knowing about regardless of which medicine you are taking.

How Wegovy's cardiovascular indication fits into the wider picture for UK patients

In the UK, semaglutide (Wegovy) holds MHRA approval for weight management and for cardiovascular risk reduction in eligible adults with established heart disease, two separate but overlapping licences. The NICE appraisal of semaglutide (TA875) addresses the weight-management indication; the cardiovascular indication followed separately, informed by SELECT. NICE guidance does not automatically accompany every new indication at launch, so NHS access for the cardiovascular indication specifically may depend on local commissioning decisions.

For the weight-management licence, NICE recommends semaglutide for use within specialist weight-management services, for a maximum of two years, in adults with a BMI of 35 or above and at least one weight-related comorbidity, with lower BMI thresholds for some ethnic backgrounds. The cardiovascular indication has its own BMI criterion of 28 or above, which means some people who do not qualify under the weight-management licence may qualify under the cardiovascular one. A prescriber works through which applies to you. Some people also notice skin-related changes during treatment, and if you are experiencing flushing you may find it helpful to read about what causes a red face on Wegovy before raising it at your next review. Private treatment through a regulated pharmacy is one route for those who do not meet NHS criteria or prefer not to wait; you can read about what Wegovy costs privately to set realistic expectations before enquiring.

If you are weighing up whether this evidence is relevant to your own cardiovascular history, the people best placed to work through that with you are clinicians who can see the full picture. Check your eligibility and speak to our prescribers at the consultation page, our GPhC-registered Independent Prescribers review every application personally, the same day.